Jaguar Health (NASDAQ:JAGX) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Price Performance

Shares of NASDAQ:JAGX opened at $0.17 on Monday. The stock’s 50-day moving average price is $0.09 and its 200-day moving average price is $0.18. Jaguar Health has a 12-month low of $0.05 and a 12-month high of $1.22. The company has a quick ratio of 1.34, a current ratio of 2.00 and a debt-to-equity ratio of 6.33.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.